2.1
Pegzilarginase (Loargys, Immedica) is indicated 'for the treatment of arginase‑1 deficiency (ARG1‑D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older'.
2 Information about pegzilarginase
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for pegzilarginase.
Price
2.3
The list price for pegzilarginase is £4,690.00 per 2‑mg vial (excluding VAT, company submission).
2.4
The company has a commercial arrangement. This makes pegzilarginase available to the NHS with a discount. The size of the discount is commercial in confidence.
Sustainability
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is published on Immedica's webpage on sustainable organization and operations.